Publication: Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
dc.contributor.author | James Watson | en_US |
dc.contributor.author | Walter R.J. Taylor | en_US |
dc.contributor.author | Germana Bancone | en_US |
dc.contributor.author | Cindy S. Chu | en_US |
dc.contributor.author | Podjanee Jittamala | en_US |
dc.contributor.author | Nicholas J. White | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Nuffield Department of Clinical Medicine | en_US |
dc.date.accessioned | 2019-08-28T06:13:27Z | |
dc.date.available | 2019-08-28T06:13:27Z | |
dc.date.issued | 2018-04-20 | en_US |
dc.description.abstract | © 2018 Watson et al. Background: The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with <30% and <70% of normal G6PD activity are not given standard regimens of primaquine and tafenoquine, respectively. Both drugs are currently considered contraindicated in pregnant and lactating women. Methods: Quantitative G6PD enzyme activity data from 5198 individuals were used to estimate the proportions of heterozygous females who would be ineligible for treatment at the 30% and 70% activity thresholds, and the relationship with the severity of the deficiency. This was used to construct a simple model relating allele frequency in males to the potential population coverage of tafenoquine and primaquine under current prescribing restrictions. Findings: Independent of G6PD deficiency, the current pregnancy and lactation restrictions will exclude ~13% of females from radical cure treatment. This could be reduced to ~4% if 8-aminoquinolines can be prescribed to women breast-feeding infants older than 1 month. At a 30% activity threshold, approximately 8–19% of G6PD heterozygous women are ineligible for primaquine treatment; at a 70% threshold, 50–70% of heterozygous women and approximately 5% of G6PD wild type individuals are ineligible for tafenoquine treatment. Thus, overall in areas where the G6PDd allele frequency is >10% more than 15% of men and more than 25% of women would be unable to receive tafenoquine. In vivax malaria infected patients these proportions will be lowered by any protective effect against P. vivax conferred by G6PD deficiency. Conclusion: If tafenoquine is deployed for radical cure, primaquine will still be needed to obtain high population coverage. Better radical cure antimalarial regimens are needed. | en_US |
dc.identifier.citation | PLoS Neglected Tropical Diseases. Vol.12, No.4 (2018) | en_US |
dc.identifier.doi | 10.1371/journal.pntd.0006440 | en_US |
dc.identifier.issn | 19352735 | en_US |
dc.identifier.issn | 19352727 | en_US |
dc.identifier.other | 2-s2.0-85046340522 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/46750 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046340522&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046340522&origin=inward | en_US |